Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib
Zhen Chen, Danlei Yu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi‐Yong Sun
Topics & Concepts
OsimertinibSterol regulatory element-binding proteinCancer researchBiologyMutantT790MLung cancerEpidermal growth factor receptorCancerInternal medicineMedicineTranscription factorGeneBiochemistryGeneticsErlotinibGefitinibCancer, Lipids, and MetabolismLung Cancer Treatments and MutationsCancer Mechanisms and Therapy